Leśniak E

No ORCID on file · 4 papers in corpus · active 2019

Study types

  • other 1
2019
Current pharmaceutical biotechnology ·doi:10.2174/1389201020666190619145655

BackgroundIn the course of neoplastic diseases, a reduction in SEMA3F expression is observed, which translates into an increase in the proliferative and proangiogenic potential of cells forming the tumor and the surrounding microenvironment…

other 2019
Current pharmaceutical biotechnology ·doi:10.2174/1389201020666190717092448

BACKGROUND: VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 are important proteins involved in the induction and development of a new blood vessel network through which the tumor is properly nourished and oxygenated. OBJECTIVES: The aim of the study w…

2019
Current pharmaceutical biotechnology ·doi:10.2174/1389201020666190408112822

BackgroundEDIL3 is an extracellular matrix protein that plays a key role in angiogenesis. Changes in the pattern of its expression also affect cellular processes and the tumor microenvironment. Elevated level of EDIL3 is considered an unfav…

2019
Medical science monitor : international medical journal of experimental and clinical research ·doi:10.12659/msm.916762

BACKGROUND SEMA3B is known as an inhibitor of angiogenesis and cell proliferation. During carcinogenesis, the loss of SEMA3B function is observed, which results in the progression of neoplastic changes. The aim of this study was to evaluate…